Cream to Calm Redness. Redness Relief CalmPlex, which SkinMedica says is the first non-prescription product clinically proven to reduce visible acute, UVinduced and chronic redness, is now available. The primary ingredient, CalmPlex treats the underlying causes of redness by inhibiting the release of the vasodilator prostaglandin. The formulation also contains niacinamide, incorporated to support barrier function. In clinical studies reported by the company, Redness Relief CalmPlex demonstrated a 40 percent reduction in UV-induced redness in as early as three days. It also provided significant reductions in chronic redness after one week with continued improvement through week twelve. SkinMedica Redness Relief CalmPlex is available through licensed physicians and medically supervised spas. SkinMedica.com
Kit for Eczema and Itch.
Combining two products intended to soothe and heal skin is the HylatopicPlus- Aurstat Kit for eczema and itch relief from Onset Dermatologics. The kit includes HylatopicPlus Emollient Foam to manage and relieve burning, itch and pain and Aurstat Skin & Wound HydroGel, which is used to relieve skin irritation, minor abrasions, and lacerations. HylatopicPlus Emollient Foam is formulated to rapidly hydrate the stratum corneum and provide a semi-permeable barrier that protects against irritants and excessive water loss, Onset says. Aurstat HydroGel contains a unique shelf-stable formulation of hypochlorous acid in hydrogel form. In a laboratory setting, Aurstat killed 99.99% of S. aureus within 30 seconds post-application. Aurstat HydroGel is non-irritating and can be safely used around the eyes, nose and mouth. OnsetDermatologics.com.
Sun Shield Offers Broad-Spectrum Protection. The latest addition to Obagi's Nu-Derm line, Sun Shield SPF 50 combines UVB absorption and UVA blockage for high SPF protection and an elegant, matte finish intended for use on nearly all skin types. Nu-Derm Sun Shield SPF 50 features 10.5% zinc oxide and 7.5% octinoxate. Another product in the The Nu-Derm line, Nu-Derm Clear, was recently awarded a Beauty Choice Award for Best Overall Dark Spot Eraser and Obagi was named Best Overall Brand Sold at a Doctor's Office by New Beauty magazine. Obagi.com.
Ultra Formulation for Reactive Skin. Preservative-, paraben-, fragrance-, alcohol-, colorant-, and lanolin-free, Toleriane Ultra from La Roche Posay is now available as a daily moisturizer to reduce signs of skin reactivity. The formulation contains neurosensine, a calming agent that the company says helps reduce signs of skin reactivity immediately upon application. Toleriane Ultra is specially packaged to reduce contamination, oxidation, and waste. LaRochePosay.us
Professional Rosacea Treatment Introduced. A new professional topical treatment for patients with acne rosacea and seborrheic rosacea, Rx Systems Acne Rosacea Therapy is designed to exfoliate dead and damaged skin cells and enhance enzymatic activity to improve skin texture, decrease pore size, and restore normal pH to the skin. According to the company, patients will see improved skin color and clarity, increased hydration, improved skin texture, and improved elasticity and firmness. Acne Rosacea Therapy is administered by medical professionals and medical salons. RxSystemspf.com.
Foaming Sunscreens Now Available. Coppertone's new Oil Free Foaming Sunscreen Lotion SPF 75+ and Water Babies Sunscreen Foaming Lotion SPF 75, offer broad spectrum UV protection for children and adults. The first mass-marketed foaming sunscreens, they are intended to be light, moisture-rich, quickly absorbing, and water-proof, the company says. The SPF 75+ formulation is hypoallergenic, fragrance-free, and non-comedogenic. Also new from the company is Coppertone Sport High Performance Sunscreen Lotion SPF 100+, which is waterproof and sweatproof and contains antioxidants. Water Babies Pure & Simple Sunscreen Lotion SPF 50 is a tear-free, broad spectrum, oil- and fragrance-free formulation available in a 2oz. travel size. Coppertone.com
In The Pipeline: Tofacitinib
Tofacitinib (CP-690,550, Pfizer, formerly known as tasocitinib) is an investigational oral agent for the treatment of moderate to severe plaque psoriasis that selectively inhibits the Janus kinase (JAK) pathways, blocking cytokine signaling, cytokine-induced gene expression, and activation of cells involved in immune and inflammatory response. Potentially the first oral agent specifically for the treatment of psoriasis, it appears to present some advantages to achieving strong clinical outcomes. “The manner in which this agent impacts pathways of cytokine signaling does not appear to be impacted by weight,” notes Alan Menter, MD, Professor of Dermatology at Baylor University Medical Center. With the average weight of psoriasis patients being notably higher than that of the general population, having a biologic agent that does not appear to be affected by weight may be a positive development, he says.
Safety and efficacy data for tofacitinib have been encouraging, says Dr. Menter. In a phase II study, tofacitinib met the primary endpoint of a statistically significantly greater proportion of patients achieving PASI 75 response at week 12 compared to placebo. Specifically, PASI 75 response for 2, 5, and 15mg tofacitinib BID groups were 25 percent, 41 percent, and 67 percent, respectively. Moreover, PASI 90 responses were 15 percent, 18 percent, and 33 percent, respectively. Regarding safety, 115 of 197 patients experienced treatment-emergent adverse events, the most frequent of which were upper respiratory tract infections and headaches. Three patients experienced a total of five serious adverse events during the phase II study.
Based on encouraging phase II results, Pfizer has initiated a phase III program called the Oral Psoriasis Treatment (OPT) trials, which are ongoing. Clinicians and researchers anticipate learning more about the long-term safety and efficacy of this agent. Dr. Menter emphasizes that if the data hold up in phase III trials, tofacitinib could play an important role in the treatment of psoriasis in coming years, due to its unique mechanism of action and mode of delivery. Says Dr. Menter, “With only about 15 percent of psoriasis patients undergoing biologic therapy, the addition of a new compound with a unique mechanism of action and strong clinical outcomes and safety data could represent a significant development in psoriasis treatment.”